Suzhou Fushilai Pharmaceutical Reports Significant Profit Growth and Cost Reductions

Suzhou Fushilai Pharmaceutical Co., Ltd., a player in the specialty chemicals sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company's valuation score has been revised, indicating a transition to a more favorable assessment. This change is supported by a significant increase in net profit for the quarter ending September 2025, which reached CNY 17.15 million, marking a remarkable growth of 409% year-over-year. Additionally, the company has experienced a reduction in raw material costs, which fell by 30.27% compared to the previous year. This cost efficiency is complemented by an impressive inventory turnover ratio of 2.7 times, suggesting effective management of stock levels. Despite the adjustments in technical indicators, the overall financial landscape for Suzhou Fushilai remains compelling, with a return on equity (ROE) of 1.97% and a price-to-book value of 0.00, highlighting its attractive valuation. For those interested in further insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.